Last reviewed · How we verify
Muscoril (THIOCOLCHICOSIDE)
Muscoril (generic name: THIOCOLCHICOSIDE) is a drug. It is currently in Phase 3 development for Spasticity.
Muscoril is a small molecule medication used to treat Myofascial Pain Syndromes, specifically cervical myofascial pain syndrome. It contains thiocolchicoside as its active ingredient.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | THIOCOLCHICOSIDE |
|---|---|
| Target | GABA A receptor alpha-1/beta-1/gamma-2, GABA A receptor alpha-2/beta-2/gamma-2, GABA-A receptor alpha-1/beta-2/gamma-2 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
- Spasticity
Common side effects
Key clinical trials
- Assessing the Benefits of Dry Needling for Low Back Pain When Combined With Regular Treatment (PHASE4)
- Comparison of the Efficacy of Mesotherapy and Extracorporeal Shock Wave Therapy in Patients With Lateral Epicondylitis (NA)
- Physiotherapy in Emergency Department for Acute Lumbar Spasm
- Mesotherapy Treatment of Irritable Bowel Syndrome (PHASE2)
- Comparison of the Efficacy of Dextrose Prolotherapy and Mesotherapy in Lateral Epicondylitis (NA)
- Extracorporeal Shockwave Therapy vs Mesotherapy in the Treatment of Myofascial Pain Syndrome: a Case-control Study (NA)
- Evaluation of the Efficacy of Different Drugs in the Treatment of the Pain in Patients With Temporomandibular Disorder (PHASE4)
- Evaluation of the Effects of Treatments Applied to Patients With Facial Myalgia on Occlusion Parameters (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Muscoril CI brief — competitive landscape report
- Muscoril updates RSS · CI watch RSS
Frequently asked questions about Muscoril
What is Muscoril?
What is Muscoril used for?
What is the generic name of Muscoril?
What development phase is Muscoril in?
What does Muscoril target?
Related
- Target: All drugs targeting GABA A receptor alpha-1/beta-1/gamma-2, GABA A receptor alpha-2/beta-2/gamma-2, GABA-A receptor alpha-1/beta-2/gamma-2
- Therapeutic area: All drugs in Other
- Indication: Drugs for Spasticity
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing